Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com.
Disclaimer: Reposts and posts of contents are for informational purposes only and do not constitute endorsements or promotions of any third-party products, services or organizations (including any statements, views or conducts by such organizations) unless explicitly stated otherwise.
Company Details
- Employees
- 60
- Founded
- -
- Address
- 1065 E Hillsdale Blvd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ternspharma.com
- HQ
- Foster City, California
Terns Pharmaceuticals Questions
Terns Pharmaceuticals's website is ternspharma.com
Terns Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/ternspharmaceuticals
Terns Pharmaceuticals has
60 employees.
View email and phone details for 60
employees at Terns Pharmaceuticals.
Terns Pharmaceuticals's industry is
Biotechnology Research
Terns Pharmaceuticals's top competitors are
Viridian Therapeutics, Inc.,
89bio,
Relay Therapeutics,
Bicara Therapeutics,
Vera Therapeutics, Inc.,
Candid Therapeutics,
Oruka Therapeutics,
Akero Therapeutics,
Mbx Biosciences, Inc.,
Ionis Pharmaceuticals, Inc..
Terns Pharmaceuticals's categories are Biotechnology Research
Terns Pharmaceuticals's founding year is 2017
